Fibriant awarded Euro 16.5M EIC Accelerator funding to support RECOFIB development

Leiden, The Netherlands, 23 December 2021 – Fibriant, a scale-up biotech company focused on
the development of the RECOFIB platform, was awarded up to € 16.5 million in funding of the
European Innovation Council Accelerator program

Go to press release

By Fibriant|December 29th, 2021|Geen categorie|0 Comments

Comments are closed.

Fibriant awarded Euro 16.5M EIC Accelerator funding to support RECOFIB development

Recent Posts

Archives

Categories

Fibriant awarded Euro 16.5M EIC Accelerator funding to support RECOFIB development

Share This Story, Choose Your Platform!

Related Posts

Fibriant expands license adding recombinant human (pro)thrombin to existing recombinant fibrinogen capability – Company on track for clinical studies with RecoSeelTM in mild-to-moderate bleeding in 2021

Fibriant CEO Jaap Koopman to present at the 11th annual Biotech Showcase event 2019 on January 7 at 4.30 PM in the Hilton San Francisco Union Square in San Francisco, CA, USA.

Presentation by Prof. Matthew Flick at the 25th International Fibrinogen Research Society meeting in Winston-Salem, NC, USA.

Fibriant and Biomed Elements announce collaboration to develop a new topical hemostat product to stop severe bleeding supported by a MIT grant from the province of Zuid Holland, The Netherlands.

Recent Posts

Archives

Categories